← Patent-cliff monitor small molecule SUBLOCADE BUPRENORPHINE
Loss of exclusivity June 2038 latest FDA-listed patent expiry
Company Indivior → View the full company profile on CliffBio Drug detail Brand name SUBLOCADE Active ingredient BUPRENORPHINE Strength 300MG/1.5ML (200MG/ML) Dosage form SOLUTION, EXTENDED RELEASE Route SUBCUTANEOUS Modality Small molecule FDA approval November 2017 Marketing status RX
Listed patents Patent Expires Type 10646484 June 2038 use U-2489 11000520 November 2035 use U-3111 11839611 November 2035 use U-3111 12622904 November 2035 use U-4528 8921387 January 2032 product 8975270 September 2031 product 10558394 June 2031 product 10198218 June 2031 use U-2489 9782402 June 2031 product 9272044 June 2031 use U-2177 9498432 June 2031 product 9827241 June 2031 product 10592168 June 2031 use U-2489
Regulatory exclusivity Code Expires M-314 February 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.